000119312515094002txt 20150316 000119312515094002hdrsgml 20150316 20150316171029 accession number 000119312515094002 conformed submission type sc 14d9a public document count 2 filed date 20150316 date change 20150316 subject company company data company conformed name salix pharmaceutical ltd central index key 0001009356 standard industrial classification pharmaceutical preparation 2834 irs number 943267443 state incorporation de fiscal year end 1231 filing value form type sc 14d9a sec act 1934 act sec file number 00553269 film number 15703900 business address street 1 8510 colonnade center drive city raleigh state nc zip 27615 business phone 919 8621000 mail address street 1 8510 colonnade center drive city raleigh state nc zip 27615 former company former conformed name salix holding ltd date name change 19970807 filed by company data company conformed name salix pharmaceutical ltd central index key 0001009356 standard industrial classification pharmaceutical preparation 2834 irs number 943267443 state incorporation de fiscal year end 1231 filing value form type sc 14d9a business address street 1 8510 colonnade center drive city raleigh state nc zip 27615 business phone 919 8621000 mail address street 1 8510 colonnade center drive city raleigh state nc zip 27615 former company former conformed name salix holding ltd date name change 19970807 sc 14d9a 1 d890045dsc14d9ahtm sc 14d9a sc 14d9a united state security exchange commission washington dc 20549 schedule 14d9 amendment no 3 solicitationrecommendation statement section 14d4 security exchange act 1934 salix pharmaceutical ltd name subject company salix pharmaceutical ltd name person filing statement common stock par value 0001 per share title class security 795435106 cusip number class security william bertrand jr acting chief operating officer executive vice president general counsel salix pharmaceutical ltd 8510 colonnade center drive raleigh north carolina 27615 919 8621000 copy to christopher t cox gregory p patti jr cadwalader wickersham taft llp one world financial center new york ny 10281 212 5046000 name address telephone number person authorized receive notice communication behalf person filing statement ¨ check box filing relates solely preliminary communication made commencement tender offer purpose amendment amendment no 3 this “amendment” amends supplement solicitationrecommendation statement schedule 14d9 salix pharmaceutical ltd the “company” “we” filed security exchange commission the “sec” march 6 2015 a heretofore amended supplemented time time “schedule 14d9” schedule 14d9 relates tender offer sun merger sub inc delaware corporation “purchaser” wholly owned subsidiary valeant pharmaceutical international delaware corporation “vpi” wholly owned subsidiary valeant pharmaceutical international inc british columbia corporation “valeant” acquire outstanding share common stock par value 0001 per share company 15800 per share net seller cash without interest le required withholding tax upon term subject condition set forth offer purchase dated march 4 2015 a amended supplemented time time “offer purchase” related letter transmittal which together offer purchase may amended supplemented time time “offer” offer described tender offer statement schedule a amended supplemented time time filed sec valeant vpi purchaser march 4 2015 march 16 2015 valeant vpi purchaser company entered amendment no 1 the “amendment” certain agreement plan merger dated february 20 2015 the “merger agreement” among company purchaser vpi and solely purpose guaranteeing vpi’s purchaser’s obligation thereunder valeant pursuant amendment among thing i offer price increased 15800 per share 17300 per share net holder cash without interest subject withholding tax required applicable law thereon provided 1200 midnight eastern time april 8 2015 one minute 1159 pm eastern time april 7 2015 condition tender offer satisfied waived valeant offer price reduced 15800 per share net holder cash without interest subject withholding tax required applicable law thereon ii amount fee payable salix upon termination merger agreement certain provision thereof increased 3564 million 4564 million iii outside date either vpi company may terminate transaction moved august 20 2015 may 1 2015 tender offer outstanding share common stock company expire 1200 midnight eastern time april 1 2015 one minute 1159 pm eastern time march 31 2015 unless extended foregoing summary amendment qualified entirety reference amendment copy attached hereto exhibit a21 incorporated herein reference expressly modified amendment merger agreement remains full force effect originally executed except otherwise set forth herein information set forth schedule 14d9 remains unchanged incorporated reference relevant item amendment capitalized term used defined herein shall meaning assigned term schedule 14d9 item 8 additional information 1 section captioned “additional information – regulatory approvals” schedule 14d9 hereby amended supplemented restating entirety third fourth paragraph section follows “pursuant hsr act valeant company filed premerger notification report form ftc antitrust division february 27 2015 march 2 2015 respectively review connection offer initial waiting period hsr act scheduled expire 1159 pm new york time march 16 2015 terminated early effective march 13 2015 accordingly hsr condition satisfied” 2 section captioned “additional information – certain litigation” schedule 14d9 hereby amended supplemented restating entirety paragraph section follows “following announcement execution merger agreement six purported stockholder class action complaint filed delaware court chancery challenging proposed transaction feinstein v valeant pharmaceutical international inc et al ca no 10721 filed february 25 2015 amended march 13 2015 garcia v salix pharmaceutical ltd et al ca no 10728 filed february 27 2015 gonsalves v salix pharmaceutical ltd et al ca no 10737 filed march 2 2015 amended march 13 2015 lindgren v salix pharmaceutical ltd et al ca no 10748 filed march 4 2015 zhang v salix pharmaceutical ltd et al ca no 10760 filed march 6 2015 herlson v salix pharmaceutical ltd et al ca no 10784 filed march 12 2015 garcia lindgren zhang herlson complaint name company board valeant vpi purchaser defendant amended complaint jointly filed feinstein gonsalves name board valeant vpi purchaser defendant dropping company defendant initial gonsalves complaint march 13 2015 plaintiff jointly filed proposed order seeking consolidation six action appointment plaintiffs’ lead counsel designation amended complaint filed feinstein operative complaint six action complaint including amended complaint alleges generally member board breached fiduciary duty stockholder defendant aided abetted breach seeking sell company inadequate consideration agreeing allegedly preclusive deal protection complaint seek among thing injunctive relief including enjoining proposed transaction rescission rescissory damage event proposed transaction consummated unspecified attorneys’ fee cost intend vigorously defend claims” 2 item 9 exhibit item 9 schedule 14d9 hereby amended supplemented adding following exhibit exhibit description document a20 joint press release issued valeant pharmaceutical international inc salix pharmaceutical ltd dated march 16 2015 incorporated reference exhibit 991 current report form 8k filed company march 16 2015 a21 amendment no 1 agreement plan merger dated march 16 2015 among valeant pharmaceutical international inc valeant pharmaceutical international sun merger sub inc salix pharmaceutical ltd incorporated reference exhibit 21 current report form 8k filed company march 16 2015 a22 communication sent company employee march 16 2015 3 signature due inquiry best knowledge belief certify information set forth amendment no 3 schedule 14d9 true complete correct salix pharmaceutical ltd by s william bertrand jr dated march 16 2015 name william c bertrand jr title acting chief operating officer executive vice president general counsel ex99a22 2 d890045dex99a22htm ex99a22 ex99a22 exhibit a22 employee letteremail dear colleague wanted let know announced amended agreement valeant increase offer acquire salix 17300 per share cash valuing salix approximately 158 billion increased offer represents 95 premium valeant’s original offer price 15800 per share announced february 22nd amended agreement valeant recognizes value salix leading gastrointestinal specialty pharmaceutical company delivers stockholder cash consideration near future last friday valeant salix received regulatory approval proceed acquisition satisfying one condition necessary consummate tender offer minimum tender condition satisfied end day march 31st valeant expects able complete acquisition april 1 please keep mind that acquisition close continue operate independent company therefore important continue focus daytoday responsibility meet commitment business deliver result customer patient stockholder always question please hesitate contact senior staff manager human resource continue best keep informed relevant information pendency transaction appreciate continued dedication delivering great highquality work always done best tom important information investor security holder communication constitute offer buy solicitation offer sell security tender offer statement schedule to including offer purchase letter transmittal related document filed security exchange commission the “sec” subsidiary valeant pharmaceutical international solicitationrecommendation statement schedule 14d9 filed sec salix pharmaceutical ltd “salix” tender offer made pursuant offer purchase letter transmittal related document filed part schedule to investor stockholder salix urged read tender offer statement solicitationrecommendation statement regarding tender offer amendment supplement thereto document filed sec become available contain or contain important information material sent free charge salix stockholder may also obtained salix’s website wwwsalixcom addition material and tender offer document filed sec available charge sec website wwwsecgov